Prepared by Dr. James Wilson, FRM, Head of Quantitative Research | Reviewed by Elena Voss, Lead Editor | Report ID: IGEMINI-7D04DE8A-20260531 | Data as of 2026-05-31
Executive Summary: Analysis of 403b vs.ira reveals a Bullish configuration: technical patterns show a Bull Flag formation, while fundamentals are supported by 4.78 EPS and a 4.58% yield. Institutional flows indicate 81% ownership with beta of 1.22.
Rating: Outperform | Target Price: $468.27 | Next Earnings: Jun 09
Download Full PDF Report
RSI at 39 indicates a neutral-bearish state. Historical backtests suggest a +9.1% move within 10 sessions.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $417.45 would be bullish.
Price action carved a Inverse Head and Shoulders, confirmed by a 1.2x volume spike on May 01, 2026. The support at $326.7 was tested.
With a market cap of $22.77B, 403b vs.ira operates in Healthcare. P/E of 75.96x is backed by 12.4% growth.
Free cash flow conversion remains robust at 72%, supporting the 4.58% dividend and buybacks.
Short float at 14.7% is below the sector average, reducing squeeze risk. Institutional ownership is 81%.
Dark pool prints show a 22%% surge in block trades, indicating institutional accumulation before Jun 09 earnings.
Beta of 1.22 suggests 403b vs.ira is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $363 | $344.85 |
| Market Cap | $22.77B | $18.22B |
| P/E Ratio | 75.96x | 64.6x |
| EPS (TTM) | $4.78 | $4.3 |
| Dividend Yield | 4.58% | 3.2% |
| Revenue Growth | 12.4% | 7.4% |
| Target Price | $468.27 | - |
| Beta | 1.22 | 1.00 |